Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 18187810)

  • 1. Predicting cisplatin and trabectedin drug sensitivity in ovarian and colon cancers.
    Stevens EV; Nishizuka S; Antony S; Reimers M; Varma S; Young L; Munson PJ; Weinstein JN; Kohn EC; Pommier Y
    Mol Cancer Ther; 2008 Jan; 7(1):10-8. PubMed ID: 18187810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trabectedin and its C subunit modified analogue PM01183 attenuate nucleotide excision repair and show activity toward platinum-resistant cells.
    Soares DG; Machado MS; Rocca CJ; Poindessous V; Ouaret D; Sarasin A; Galmarini CM; Henriques JA; Escargueil AE; Larsen AK
    Mol Cancer Ther; 2011 Aug; 10(8):1481-9. PubMed ID: 21622731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Von Hippel-Lindau-coupled and transcription-coupled nucleotide excision repair-dependent degradation of RNA polymerase II in response to trabectedin.
    Aune GJ; Takagi K; Sordet O; Guirouilh-Barbat J; Antony S; Bohr VA; Pommier Y
    Clin Cancer Res; 2008 Oct; 14(20):6449-55. PubMed ID: 18927284
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Trabectedin: Ecteinascidin 743, Ecteinascidin-743, ET 743, ET-743, NSC 684766.
    Drugs R D; 2006; 7(5):317-28. PubMed ID: 16922593
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of DNA repair-related genes in breast cancer reveals CUL4A ubiquitin ligase as a novel biomarker of trabectedin response.
    García MJ; Saucedo-Cuevas LP; Muñoz-Repeto I; Fernández V; Robles MJ; Domingo S; Palacios J; Aracil M; Nieto A; Tercero JC; Benítez J
    Mol Cancer Ther; 2013 Apr; 12(4):530-41. PubMed ID: 23364677
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of homologous recombination in trabectedin-induced DNA damage.
    Tavecchio M; Simone M; Erba E; Chiolo I; Liberi G; Foiani M; D'Incalci M; Damia G
    Eur J Cancer; 2008 Mar; 44(4):609-18. PubMed ID: 18243687
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ZNF93 increases resistance to ET-743 (Trabectedin; Yondelis) and PM00104 (Zalypsis) in human cancer cell lines.
    Duan Z; Choy E; Harmon D; Yang C; Ryu K; Schwab J; Mankin H; Hornicek FJ
    PLoS One; 2009 Sep; 4(9):e6967. PubMed ID: 19742314
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dynamics of cell cycle phase perturbations by trabectedin (ET-743) in nucleotide excision repair (NER)-deficient and NER-proficient cells, unravelled by a novel mathematical simulation approach.
    Tavecchio M; Natoli C; Ubezio P; Erba E; D'Incalci M
    Cell Prolif; 2007 Dec; 40(6):885-904. PubMed ID: 18021177
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Increased sensitivity to platinum drugs of cancer cells with acquired resistance to trabectedin.
    Colmegna B; Uboldi S; Frapolli R; Licandro SA; Panini N; Galmarini CM; Badri N; Spanswick VJ; Bingham JP; Kiakos K; Erba E; Hartley JA; D'Incalci M
    Br J Cancer; 2015 Dec; 113(12):1687-93. PubMed ID: 26633559
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The inefficiency of incisions of ecteinascidin 743-DNA adducts by the UvrABC nuclease and the unique structural feature of the DNA adducts can be used to explain the repair-dependent toxicities of this antitumor agent.
    Zewail-Foote M; Li VS; Kohn H; Bearss D; Guzman M; Hurley LH
    Chem Biol; 2001 Nov; 8(11):1033-49. PubMed ID: 11731295
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characterization of a new trabectedin-resistant myxoid liposarcoma cell line that shows collateral sensitivity to methylating agents.
    Uboldi S; Bernasconi S; Romano M; Marchini S; Fuso Nerini I; Damia G; Ganzinelli M; Marangon E; Sala F; Clivio L; Chiorino G; Di Giandomenico S; Rocchi M; Capozzi O; Margison GP; Watson AJ; Caccuri AM; Pastore A; Fossati A; Mantovani R; Grosso F; Tercero JC; Erba E; D'Incalci M
    Int J Cancer; 2012 Jul; 131(1):59-69. PubMed ID: 21805478
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Unique pattern of ET-743 activity in different cellular systems with defined deficiencies in DNA-repair pathways.
    Damia G; Silvestri S; Carrassa L; Filiberti L; Faircloth GT; Liberi G; Foiani M; D'Incalci M
    Int J Cancer; 2001 May; 92(4):583-8. PubMed ID: 11304695
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair.
    Takebayashi Y; Pourquier P; Zimonjic DB; Nakayama K; Emmert S; Ueda T; Urasaki Y; Kanzaki A; Akiyama SI; Popescu N; Kraemer KH; Pommier Y
    Nat Med; 2001 Aug; 7(8):961-6. PubMed ID: 11479630
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of action.
    Erba E; Bergamaschi D; Bassano L; Damia G; Ronzoni S; Faircloth GT; D'Incalci M
    Eur J Cancer; 2001 Jan; 37(1):97-105. PubMed ID: 11165136
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin.
    Herrero AB; Martín-Castellanos C; Marco E; Gago F; Moreno S
    Cancer Res; 2006 Aug; 66(16):8155-62. PubMed ID: 16912194
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Trabectedin (ET-743/Yondelis) for treating soft tissue sarcomas and ovarian cancer].
    Gennigens C; Jerusalem G
    Rev Med Liege; 2011; 66(7-8):452-5. PubMed ID: 21942081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ascites interferes with the activity of lurbinectedin and trabectedin: Potential role of their binding to alpha 1-acid glycoprotein.
    Erba E; Romano M; Gobbi M; Zucchetti M; Ferrari M; Matteo C; Panini N; Colmegna B; Caratti G; Porcu L; Fruscio R; Perlangeli MV; Mezzanzanica D; Lorusso D; Raspagliesi F; D'Incalci M
    Biochem Pharmacol; 2017 Nov; 144():52-62. PubMed ID: 28782526
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of ATR and ATM potentiates the activity of trabectedin and lurbinectedin by perturbing the DNA damage response and homologous recombination repair.
    Lima M; Bouzid H; Soares DG; Selle F; Morel C; Galmarini CM; Henriques JA; Larsen AK; Escargueil AE
    Oncotarget; 2016 May; 7(18):25885-901. PubMed ID: 27029031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of BRCA1 and XPG mutations on treatment response to trabectedin and pegylated liposomal doxorubicin in patients with advanced ovarian cancer: exploratory analysis of the phase 3 OVA-301 study.
    Monk BJ; Ghatage P; Parekh T; Henitz E; Knoblauch R; Matos-Pita AS; Nieto A; Park YC; Cheng PS; Li W; Favis R; Ricci D; Poveda A
    Ann Oncol; 2015 May; 26(5):914-920. PubMed ID: 25722380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Transcriptional signature of Ecteinascidin 743 (Yondelis, Trabectedin) in human sarcoma cells explanted from chemo-naive patients.
    Martínez N; Sánchez-Beato M; Carnero A; Moneo V; Tercero JC; Fernández I; Navarrete M; Jimeno J; Piris MA
    Mol Cancer Ther; 2005 May; 4(5):814-23. PubMed ID: 15897246
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.